EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Early Treatment with Pegylated Interferon Lambda for Covid-19

Gilmar Reis iD, Eduardo A S Moreira Silva, Daniela C Medeiros Silva, Lehana Thabane, Vitoria H S Campos, Thiago S Ferreira, Castilho V Q Santos, Ana M R Nogueira, Ana P F G Almeida, Leonardo C M Savassi, Adhemar D Figueiredo-Neto, Ana C F Dias und 30 weitere

New England Journal of Medicine · 09.02.2023 · 388 (6) · 518-528

DOI: 10.1056/nejmoa2209760 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.02.2023. Verfasst von Gilmar Reis und 41 weiteren Autor:innen. Beteiligte Einrichtung: From ViRx@Stanford, Stanford Biosecurity and Pandemic Preparedness Initiative (G.R., J.S.G., E.J.M.), and the Departments of Medicine (Division of Ga…. Hauptthemen laut MEDLINE: COVID-19, Interferon Lambda, COVID-19 Drug Treatment. Die Arbeit wurde bisher 179-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Rainwater Charitable Foundation, Eiger BioPharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Interferon LambdaCOVID-19 Drug TreatmentAdultHumansBayes TheoremDouble-Blind MethodPolyethylene GlycolsSARS-CoV-2Treatment OutcomeAmbulatory CareInjections, SubcutaneousAntiviral AgentsCOVID-19 VaccinesVaccination

Substanzen

Interferon LambdaPolyethylene GlycolsAntiviral AgentsCOVID-19 Vaccines

Autor:innen und Institutionen

  • From ViRx@Stanford, Stanford Biosecurity and Pandemic Preparedness Initiative (G.R., J.S.G., E.J.M.), and the Departments of Medicine (Division of Gastroenterology and Hepatology) and Microbiology and Immunology, Stanfo…

ORCID-Profile: Gilmar Reis, Ofir Harari

Förderung

  • NIAID NIH HHS
  • Rainwater Charitable Foundation
  • Eiger BioPharmaceuticals
  • FastGrants
  • Bill and Melinda Gates Foundation
  • FTX Foundation

Zitieren

APA

Reis, G., Moreira Silva, E. A. S., Medeiros Silva, D. C., Thabane, L., Campos, V. H. S., Ferreira, T. S., Santos, C. V. Q., Nogueira, A. M. R., Almeida, A. P. F. G., Savassi, L. C. M., Figueiredo-Neto, A. D., Dias, A. C. F., Freire Júnior, A. M., Bitarães, C., Milagres, A. C., Callegari, E. D., Simplicio, M. I. C., Ribeiro, L. B., Oliveira, R., …, & TOGETHER Investigators (2023). Early Treatment with Pegylated Interferon Lambda for Covid-19. New England Journal of Medicine, 388(6), 518-528. https://doi.org/10.1056/nejmoa2209760

Vancouver

Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, Ferreira TS, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. New England Journal of Medicine. 2023;388(6):518-528. doi:10.1056/nejmoa2209760

BibTeX
@article{Reis2023,
  author = {Reis, Gilmar and Moreira Silva, Eduardo A S and Medeiros Silva, Daniela C and Thabane, Lehana and Campos, Vitoria H S and Ferreira, Thiago S and Santos, Castilho V Q and Nogueira, Ana M R and Almeida, Ana P F G and Savassi, Leonardo C M and Figueiredo-Neto, Adhemar D and Dias, Ana C F and Freire Júnior, Adelino M and Bitarães, Carina and Milagres, Aline C and Callegari, Eduardo D and Simplicio, Maria I C and Ribeiro, Luciene B and Oliveira, Rosemary and Harari, Ofir and Wilson, Lindsay A and Forrest, Jamie I and Ruton, Hinda and Sprague, Sheila and McKay, Paula and Guo, Christina M and Limbrick-Oldfield, Eve H and Kanters, Steve and Guyatt, Gordon H and Rayner, Craig R and Kandel, Christopher and Biondi, Mia J and Kozak, Robert and Hansen, Bettina and Zahoor, M Atif and Arora, Paul and Hislop, Colin and Choong, Ingrid and Feld, Jordan J and Mills, Edward J and Glenn, Jeffrey S and TOGETHER Investigators, TOGETHER Investigators},
  title = {Early Treatment with Pegylated Interferon Lambda for Covid-19},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {6},
  pages = {518--528},
  doi = {10.1056/nejmoa2209760}
}
Kostenlos starten →